Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is approximately 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts priced targets range from a high of hundred one dolars to a low of sixty one dolars.
In the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management strategies. The retail or Long Term Care segment includes selling of prescribed drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products as well as similar services, which includes medical, pharmacy, dental, behavioural health, medical control abilities. The Corporate segment involves in providing management as well as administrative services. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.